{"product_id":"edgewisetx-pestle-analysis","title":"Edgewise Therapeutics PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE snapshot reveals how regulation, biotech funding cycles, and rapid tech advances shape Edgewise Therapeutics’ strategic risks and opportunities—concise, actionable, and investor-focused. Purchase the full PESTLE to access detailed legal, economic, and scientific drivers, scenario analysis, and ready-to-use slides for decisions and pitches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Regulatory Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA emphasis on accelerated pathways for rare diseases remains a key political driver; by end-2025, the agency reported 65% of orphan drug designations using expedited programs, pressuring sponsors to adapt.\u003c\/p\u003e\n\u003cp\u003ePolitical focus on Duchenne and Becker has led to broader acceptance of surrogate and functional endpoints; FDA advisory trends show 18% more flexibility in 2024–25 reviews.\u003c\/p\u003e\n\u003cp\u003eEdgewise must align its small-molecule program with evolving endpoint standards and demonstrate safety\/efficacy to satisfy federal requirements and potential accelerated approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act’s drug negotiation program, which could begin targeting select drugs by 2026 and has already projected federal savings of $100+ billion through 2029, forces biopharma to assume price pressure in long-term planning.\u003c\/p\u003e\n\u003cp\u003eDebate over orphan drug exemptions persists in Congress, with proposals in 2024–25 seeking to narrow eligibility after orphan-designated products accounted for roughly 10% of US drug spend in recent years.\u003c\/p\u003e\n\u003cp\u003eEdgewise must track potential adjustments to the Small Molecule Penalty—changes could materially reduce net pricing for oral therapies and compress long-term revenue forecasts used in DCF models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal support via NIH and federal grants underpins rare disease work; NIH funding to musculoskeletal research rose to about $1.9B in FY2023 but faces variability as budget committee shifts in Congress can cut or redirect allocations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical stability in APAC and India, which supply roughly 60% of global active pharmaceutical ingredients, is critical for Edgewise Therapeutics to maintain clinical and commercial supply continuity.\u003c\/p\u003e\n\u003cp\u003eTrade policies and tariffs projected through end-2025—including potential US tariffs of up to 10% on certain chemicals—could raise small-molecule input costs, impacting gross margins on drug candidates.\u003c\/p\u003e\n\u003cp\u003eRising geopolitical tensions prompt a shift toward diversified or regionalized sourcing; relocating 20–30% of API volumes could reduce disruption risk but raise logistics and capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60% of APIs sourced from APAC\/India\u003c\/li\u003e\n\u003cli\u003ePotential tariffs up to 10% by end-2025\u003c\/li\u003e\n\u003cli\u003eConsider shifting 20–30% of API volume for resilience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Lobbying\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePowerful advocacy groups like Parent Project Muscular Dystrophy, which helped secure \u0026gt;$1.2B in U.S. federal rare disease funding in 2024, exert strong influence on drug approval priorities and insurance mandates, accelerating pathways for therapies targeting Duchenne and related disorders.\u003c\/p\u003e\n\u003cp\u003eThese organizations lobby for legislative changes—such as expanded accelerated approval and coverage mandates—boosting access to breakthrough treatments and shortening time-to-market for companies like Edgewise.\u003c\/p\u003e\n\u003cp\u003eEdgewise benefits from this political momentum: sustained advocacy keeps rare muscle disorders prioritized in federal research budgets and payer discussions, improving commercial prospects and reimbursement visibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy-driven $1.2B+ rare disease funding (2024)\u003c\/li\u003e\n\u003cli\u003eStronger push for accelerated approval and coverage mandates\u003c\/li\u003e\n\u003cli\u003eIncreased political visibility enhances Edgewise commercialization and reimbursement prospects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise Poised by Rare‑Disease Tailwinds but Faces Pricing, Supply \u0026amp; Evidence Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory emphasis on accelerated rare-disease pathways (65% orphan expedited use by end-2025) and flexible Duchenne endpoints (+18% in 2024–25) favors Edgewise but raises evidentiary demands; IRA negotiation and orphan reform debates threaten pricing; API sourcing (≈60% APAC\/India) and potential tariffs (up to 10%) pose supply\/cost risks; advocacy drove $1.2B+ rare-disease funding in 2024, aiding reimbursement visibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan expedited use (end-2025)\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuchenne endpoint flexibility (2024–25)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI sourcing from APAC\/India\u003c\/td\u003e\n\u003ctd\u003e≈60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential tariffs\u003c\/td\u003e\n\u003ctd\u003eup to 10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy-driven funding (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely affect Edgewise Therapeutics across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section grounded in current industry trends and data to identify risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise PESTLE summary of Edgewise Therapeutics highlighting regulatory, market, technological, and socio-economic factors to streamline risk discussions and strategic planning during meetings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of capital is critical for clinical-stage Edgewise, which had cash and equivalents of about $158.6m as of 9\/30\/2025, given estimated Phase 3 costs often exceeding $200–300m per program.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, Fed funds near 5.25–5.50% and constrained biotech IPOs\/secondary activity reduce investor appetite for high-risk biotech, affecting timing of follow-on offerings.\u003c\/p\u003e\n\u003cp\u003eMaintaining a strong balance sheet is vital to fund late-stage trials without dilutive equity raises; Edgewise’s burn rate and runway metrics will determine dilution risk amid market volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Commercialization Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBringing a rare disease drug to market incurs specialized marketing and distribution costs often 2–5x higher than primary care drugs; orphan launch costs can exceed $150–250M due to targeted outreach and logistics.\u003c\/p\u003e\n\u003cp\u003eEdgewise’s economic model depends on premium pricing—U.S. orphan drug list prices averaged over $200,000\/year in 2024—contingent on demonstrating clear clinical benefit vs standard of care.\u003c\/p\u003e\n\u003cp\u003eStrategic plans must budget for high patient-identification costs (registry and genetic testing spend) and a specialized sales force targeting neuromuscular specialists, where payer access efforts raise pre-launch expenses by tens of millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer Reimbursement Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsurance firms and PBMs are increasingly scrutinizing high-cost orphan drugs; in 2024, 78% of US payers reported stricter review policies for speciality therapies, pressuring Edgewise on pricing and outcomes.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the shift to value-based care means Edgewise must show reduced hospitalizations or total cost of care; CMS and commercial pilots tie outcomes to rebates and shared savings, affecting revenue realization.\u003c\/p\u003e\n\u003cp\u003eEconomic success depends on favorable formulary placement and managing prior authorization burdens—70% of specialty prescriptions face PA delays—making payer contracting and real-world evidence generation critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePersistent global inflation—headline CPI around 3.4% in 2024 in major markets—raises costs for clinical trial supplies, shipping, and specialist staff, increasing per-patient trial expenses for Edgewise Therapeutics.\u003c\/p\u003e\n\u003cp\u003eHigher wage inflation and supplier price increases can accelerate burn rate, risking a shortened cash runway unless capital planning is tightened; biotech median cash runway was ~18 months in 2024.\u003c\/p\u003e\n\u003cp\u003eContract Research Organization fees rose an estimated 5–8% YoY in 2024, forcing Edgewise to adopt stricter financial forecasting and cost-containment measures such as milestone-based contracts and renegotiation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInflation increases trial input costs and wages\u003c\/li\u003e\n\u003cli\u003eMedian biotech cash runway ~18 months (2024)\u003c\/li\u003e\n\u003cli\u003eCRO fees up ~5–8% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eNeed for tighter forecasting, milestone contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Sector M\u0026amp;A Activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe pharmaceutical sector's economic health drives M\u0026amp;A; Big Pharma completed $210B in life-science deals in 2024–25, increasing odds Edgewise is bought or partners with a larger firm to refill pipelines facing patent cliffs.\u003c\/p\u003e\n\u003cp\u003eLate-2025 valuation for Edgewise hinges on consolidation trends and premiums for rare-disease assets, where median deal premiums reached ~45% in 2024 for rare-asset transactions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig Pharma deal flow: $210B (2024–25)\u003c\/li\u003e\n\u003cli\u003eMedian premium for rare-disease assets: ~45% (2024)\u003c\/li\u003e\n\u003cli\u003ePatent-cliff-driven acquisitions rising\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise faces dilution risk as cash falls short of Phase 3 amid tight market and payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh cost of capital and ~18-month median biotech runway (2024) heighten dilution risk for Edgewise; cash $158.6M (9\/30\/2025) vs Phase 3 needs $200–300M. Fed funds ~5.25–5.50% (late‑2025) and weak IPO\/secondary markets constrain follow‑on timing. Orphan pricing potential \u0026gt;$200k\/year (2024) offset by payer scrutiny (78% tighter reviews, 2024) and value‑based reimbursement shifts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$158.6M (9\/30\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian runway\u003c\/td\u003e\n\u003ctd\u003e~18 months (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 cost\u003c\/td\u003e\n\u003ctd\u003e$200–300M\/program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan list price\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200,000\/yr (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer scrutiny\u003c\/td\u003e\n\u003ctd\u003e78% tighter reviews (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEdgewise Therapeutics PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Edgewise Therapeutics PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use; it includes the same content, insights, and layout visible now with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751423193465,"sku":"edgewisetx-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/edgewisetx-pestle-analysis.png?v=1772231207","url":"https:\/\/matrixbcg.com\/products\/edgewisetx-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}